Thelansis

Parkinson’s Disease Market Outlook Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Parkinson’s Disease Overview Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein into Lewy bodies. This pathology disrupts basal ganglia motor loops, causing bradykinesia, resting tremor, rigidity, and postural instability. Genetic risk leans heavily on  GBA1 ...

Parkinson’s Disease Market Outlook Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s traject...

Parkinson’s Disease Market Outlook Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

Parkinson’s Disease Market Outlook Thelansis’s “Parkinson’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parkinson’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Parkinson’s Disease Overview Parkinson’s Disease (PD) is recognized as a complex, chronic, and progressive multisystem neurodegenerative disorder, not solely a motor system disorder, resulting from the progressive loss of dopamine-producing neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein into Lewy bodies, which also spread to other brain regions and the peripheral nervous system years before...

  AbbVie announced that the U.S. FDA has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating motor fluctuations in adults with advanced Parkinson’s disease (PD). Robert A. Hauser, M.D., MBA, Professor of Neurology and Director of the Parkinson’s and Movement Disorder Center at the University of South Florida, highlighted that this new, non-surgical regimen provides continuous delivery of levodopa morning, day and night. Publish Date: 17-10-2024   Source: AbbVie Parkinson’s disease, a chronic and progressive disorder of the central nervous system, falls under the category of motor system disorders. This condition stems from the loss of cells in the substantia nigra region of the brain, which are responsible for producing dopamine, a crucial neurotransmitter facilitating communication within the brain. Dopamine ensures the smooth and coordinated operation of the body’s muscles and mov...

 Parkinson's disease, a chronic and progressive disorder of the central nervous system, falls under the category of motor system disorders. This condition stems from the loss of cells in the substantia nigra region of the brain, which are responsible for producing dopamine, a crucial neurotransmitter facilitating communication within the brain. Dopamine ensures the smooth and coordinated operation of the body's muscles and movement. Consequently, the depletion of dopamine results in uncontrolled neuronal activity, leaving individuals incapable of managing or directing their movements. The symptoms of Parkinson's disease typically manifest gradually and intensify over time. These symptoms can encompass tremors or shaking, challenges in maintaining balance and walking, stiffness in the limbs and torso, and a general slowing down of movement, medically known as bradykinesia. Patients often struggle with basic activities like walking, speaking, and completing simple tasks. Typi...